# ヒト遺伝学市場

> ヒト遺伝学市場調査報告書 情報 アプリケーション別（ウェルネス＆Eコマース、予防医療、診断＆治療）、テスト別（NIPT、キャリアテスト、ファーマコゲノミクステスト、核型検査、血栓症検査、セプチン9バイオマーカー検査、NGS、その他）および地域別（北米、ヨーロッパ、アジア太平洋、その他の地域）–2035年までの市場予測

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.8%
- **2024:** $ 31.79 Billion
- **2025:** $ 35.22 Billion
- **2035:** $ 98.24 Billion
- **Key Players:** Illumina(US), Thermo Fisher Scientific (US), Roche(CH), Abbott Laboratories (US), PerkinElmer (US), Agilent Technologies (US), BGI Genomics (CN), Myriad Genetics (US), Genomatix (DE)

**Report ID:** MRFR/LS/0243-CR · **Pages:** 169 · **Author:** Nidhi Mandole & Kinjoll Dey · **Last Updated:** September 27, 2026

**URL:** https://www.marketresearchfuture.com/reports/human-genetics-market-714

---

## Market Summary

As per MRFR analysis, the Human Genetics Market was estimated at 31.79 USD Billion in 2024. The Human Genetics industry is projected to grow from 35.22 USD Billion in 2025 to 98.24 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 10.8% during the forecast period 2025 - 2035.

## Market Drivers

### Market Growth Projections

The Human Genetics Market is poised for substantial growth, with projections indicating a market value of 31.8 USD Billion in 2024 and an anticipated rise to 98.2 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate of 10.8% from 2025 to 2035. 
 
The expansion is driven by various factors, including advancements in genetic testing technologies, increasing prevalence of genetic disorders, and the growing demand for personalized medicine. As the industry evolves, it is likely to attract further investments and innovations, solidifying its position as a critical component of modern healthcare.

### Government Initiatives and Funding

Government initiatives and funding play a crucial role in propelling the Human Genetics Market forward. Various countries are investing in genetic research and healthcare infrastructure to enhance disease prevention and treatment strategies. 
 
For instance, the National Institutes of Health in the United States allocates substantial resources for genomic research, fostering innovation in genetic therapies. Such governmental support not only accelerates research but also encourages public-private partnerships, leading to the development of novel genetic solutions. This supportive environment is likely to contribute to the market's growth trajectory, with projections indicating a rise from 31.8 USD Billion in 2024 to 98.2 USD Billion by 2035.

### Increasing Awareness and Education

The rising awareness and education regarding genetic health are vital drivers in the Global Human Genetics Market. Public health campaigns and educational programs are informing individuals about the importance of genetic testing and its implications for health management. This heightened awareness is leading to increased demand for genetic services, as individuals seek proactive measures for disease prevention. 
 
Moreover, healthcare professionals are becoming more knowledgeable about genetic testing options, further driving adoption rates. As awareness continues to grow, the market is expected to expand significantly, with a valuation of 31.8 USD Billion in 2024 and a projected increase to 98.2 USD Billion by 2035.

### Rising Prevalence of Genetic Disorders

The increasing incidence of genetic disorders globally drives the Global Human Genetics Market. Conditions such as cystic fibrosis, sickle cell anemia, and various hereditary cancers are becoming more prevalent, necessitating advanced genetic testing and therapies. 
 
For instance, the World Health Organization reports that genetic disorders affect approximately 1 in 160 children globally. This growing demand for genetic diagnostics and personalized medicine is projected to contribute significantly to the market, with an estimated value of 31.8 USD Billion in 2024, and a forecasted growth to 98.2 USD Billion by 2035, reflecting a compound annual growth rate of 10.8% from 2025 to 2035.

### Growing Demand for Personalized Medicine

The shift towards personalized medicine is a pivotal driver in the Human Genetics Market. Patients increasingly seek treatments tailored to their genetic profiles, enhancing therapeutic efficacy and minimizing adverse effects. This trend is evident in oncology, where targeted therapies based on genetic mutations have shown improved outcomes. 
 
The market's expansion is further supported by the increasing awareness of genetic testing among healthcare providers and patients. As a result, the market is projected to grow significantly, with a valuation of 31.8 USD Billion in 2024 and an expected rise to 98.2 USD Billion by 2035, indicating a robust CAGR of 10.8% from 2025 to 2035.

### Advancements in Genetic Testing Technologies

Technological innovations in genetic testing are revolutionizing the market. The development of next-generation sequencing and CRISPR gene-editing technologies has enhanced the accuracy and efficiency of genetic analyses. These advancements allow for comprehensive genomic profiling, enabling early detection of diseases and tailored treatment plans. 
 
For example, companies are now offering whole-genome sequencing at reduced costs, making it accessible to a broader population. As these technologies continue to evolve, they are expected to drive market growth, contributing to the anticipated increase in market value from 31.8 USD Billion in 2024 to 98.2 USD Billion by 2035.

## Future Outlook

ヒト遺伝学市場は、2025年から2035年までの10.8%のCAGRで成長することが予測されており、これはゲノム技術の進歩、個別化医療、遺伝子検査の需要の増加によって推進されます。

**New opportunities:**

- 診断精度を向上させるために、AI駆動の遺伝子分析ツールを開発します。遺伝カウンセリングのための遠隔医療サービスを拡大し、サービスが行き届いていない地域に届くようにします。バイオテクノロジー企業とのパートナーシップに投資し、遺伝子治療の革新を図ります。

2035年までに、ヒト遺伝学市場は医療革新において重要なセクターになると期待されています。

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America is poised to maintain its leadership in the Human Genetics Market, holding a significant market share of 15.89 in 2024. The region's growth is driven by advanced research facilities, high healthcare expenditure, and a robust regulatory framework that encourages innovation. Increasing demand for genetic testing and personalized medicine further propels market expansion, supported by government initiatives promoting genomics research.

The competitive landscape in North America is characterized by the presence of key players such as Illumina, Thermo Fisher Scientific, and Abbott Laboratories. These companies are at the forefront of technological advancements, offering a wide range of genetic testing solutions. The U.S. and Canada are leading countries, with substantial investments in R&D and collaborations between public and private sectors, ensuring a dynamic market environment.

### Europe : Emerging Market with Growth Potential

Europe's Human Genetics Market is poised for growth, with a market size of 9.53 in 2024. The region benefits from a strong emphasis on research and development, supported by EU funding and initiatives aimed at advancing genetic research. Europe's mrket is poised for growth, with strong contributions from countries such as Germany, making the Germany market a key regional driver. Regulatory frameworks like GDPR support ethical genetic practices.

Regulatory frameworks, such as the General Data Protection Regulation (GDPR), ensure ethical standards in genetic testing, fostering consumer trust and market demand. Leading countries in Europe include Germany, the UK, and France, where significant investments in biotechnology and healthcare infrastructure are evident. Key players like QIAGEN and Roche are actively involved in expanding their product offerings. The competitive landscape is evolving, with a focus on collaboration between academic institutions and industry, enhancing innovation in genetic testing and therapies.

### Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific region is witnessing rapid growth in the market, with a market size of 5.95 in 2024. Factors such as increasing healthcare expenditure, rising awareness of genetic disorders, and advancements in technology are driving demand. Governments are implementing supportive policies to enhance research capabilities and access to genetic testing, contributing to market expansion.

Countries like China and Japan are leading the charge, with significant investments in biotechnology and healthcare infrastructure. Countries like China are leading this expansion, positioning the China market as a major contributor to global growth. The presence of companies like BGI Genomics and Genomatix highlights the competitive landscape. Collaborations between public and private sectors are fostering innovation, positioning Asia-Pacific as a key player in the global human genetics arena.

### Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa (MEA) region, with a market size of 0.42 in 2024, presents unique challenges and opportunities in the market. Limited access to advanced healthcare services and genetic testing facilities hampers growth. However, increasing awareness of genetic disorders and government initiatives to improve healthcare infrastructure are driving demand for genetic solutions.

Countries like South Africa and the UAE are making strides in genetic research and testing, supported by investments from both public and private sectors. Increasing investments and awareness are contributing to the development of the market GCC, particularly in countries like the UAE. The competitive landscape is gradually evolving, with local and international players seeking to establish a foothold in the region. Collaborative efforts are essential to overcome existing barriers and unlock the market's potential.

## Competitive Benchmarking

The Human Genetics Market is characterized by a dynamic competitive landscape, driven by advancements in genomic technologies and increasing demand for personalized medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Roche (CH) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Illumina (US) focuses on expanding its sequencing capabilities, while Thermo Fisher Scientific (US) emphasizes its comprehensive portfolio of genetic analysis tools.
 
Roche (CH) is actively pursuing collaborations to integrate diagnostics with therapeutic solutions, thereby shaping a competitive environment that prioritizes technological advancement and customer-centric solutions. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with a mix of established players and emerging companies vying for market share. The collective influence of these key players fosters a competitive structure that encourages innovation and responsiveness to market demands, ultimately benefiting end-users through improved product offerings and services.
 
In November 2025, Illumina (US) announced a strategic partnership with a leading healthcare provider to enhance genomic testing accessibility. This collaboration aims to streamline the integration of genomic data into clinical workflows, potentially revolutionizing patient care by enabling more personalized treatment plans. The strategic importance of this partnership lies in its potential to expand Illumina's reach and solidify its position as a leader in the genomic testing space.
 
In October 2025, Thermo Fisher Scientific (US) launched a new line of next-generation sequencing (NGS) products designed to improve throughput and reduce costs for laboratories. This product launch is significant as it addresses the growing demand for efficient and cost-effective genetic analysis solutions, positioning Thermo Fisher as a key player in the competitive landscape. The introduction of these products may enhance customer loyalty and attract new clients seeking advanced genomic technologies.
 
In September 2025, Roche (CH) acquired a biotechnology firm specializing in CRISPR technology, aiming to bolster its research and development capabilities in gene editing. This acquisition is strategically important as it aligns with Roche's commitment to advancing precision medicine and expanding its therapeutic offerings. By integrating CRISPR technology, Roche could potentially accelerate the development of innovative treatments, thereby enhancing its competitive edge in the market.
 
As of December 2025, current trends in the market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in genetic research and diagnostics. Strategic alliances are increasingly shaping the competitive landscape, fostering collaboration that enhances innovation and accelerates product development. Looking ahead, competitive differentiation is likely to evolve, with a greater emphasis on technological innovation and supply chain reliability, moving away from traditional price-based competition. Companies that successfully navigate these trends will likely emerge as leaders in the market.

## Recent News & Developments

January 2026, Thermo Fisher introduced the SwiftArrayStudio microarray analyzer, designed for fast and scalable sample analysis — extending its Applied Biosystems genomic array portfolio (used for SNP genotyping, disease-risk research, and population-scale genetic studies) with improved throughput. (Source: [captodayonline.com](https://www.captodayonline.com/tag/thermo-fisher-scientific/))

June 2026, Roche received CE Mark approval for its Elecsys ApoE4 biomarker blood test — the first IVD immunoassay to identify carriers of the ApoE4 Alzheimer's genetic risk variant from a blood draw — and filed with Japan's regulators for its companion Elecsys pTau217 plasma test, directly expanding accessible genetic/biomarker risk testing for a disease affecting millions. (Source: [diagnostics.roche.com](https://diagnostics.roche.com/global/en/news-listing/2026/roche-ce-mark-apoe4.html))

## Report Scope

| MARKET SIZE 2024 | 31.79(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 35.22(USD Billion) |
| MARKET SIZE 2035 | 98.24(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.8% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Abbott Laboratories (US), PerkinElmer (US), Agilent Technologies (US), BGI Genomics (CN), Myriad Genetics (US), Genomatix (DE) |
| Segments Covered | Application, Technology, End User |
| Key Market Opportunities | Advancements in gene editing technologies create transformative opportunities in the market. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: 2024年のヒト遺伝学市場の現在の評価額はどのくらいですか？**
A: ヒト遺伝学市場は2024年に317.9億米ドルと評価されました。

**Q: 2035年のヒト遺伝学市場の予測評価額はどのくらいですか？**
A: 市場は2035年までに982.4億米ドルに達すると予測されています。

**Q: 2025年から2035年の予測期間中のヒト遺伝学市場の期待CAGRはどのくらいですか？**
A: 2025年から2035年の間のヒト遺伝学市場の期待CAGRは10.8%です。

**Q: ヒト遺伝学市場の成長を促進しているアプリケーションセグメントはどれですか？**
A: 主要なアプリケーションセグメントには、病気診断、薬剤開発、遺伝子検査、個別化医療が含まれ、遺伝子検査は100億米ドルから300億米ドルに成長すると予測されています。

**Q: 医療提供者はヒト遺伝学市場にどのように貢献していますか？**
A: 医療提供者は100億米ドルから310億米ドルに拡大すると予想されており、市場における重要な役割を示しています。

**Q: ヒト遺伝学市場に影響を与えている技術は何ですか？**
A: 次世代シーケンシングやポリメラーゼ連鎖反応などの技術が重要であり、次世代シーケンシングは100億米ドルから320億米ドルに成長すると予測されています。

**Q: ヒト遺伝学市場で提供されるサービスの種類は何ですか？**
A: 市場には、ラボサービス、コンサルテーションサービス、データ分析サービスが含まれ、ラボサービスは125億米ドルから390億米ドルに増加すると予測されています。

**Q: ヒト遺伝学市場で使用されるサンプルタイプは何ですか？**
A: サンプルタイプには、血液サンプル、唾液サンプル、組織サンプル、細胞株が含まれ、血液サンプルは100億米ドルから300億米ドルに成長すると予測されています。

**Q: ヒト遺伝学市場の主要なプレーヤーは誰ですか？**
A: 主要なプレーヤーには、イルミナ、サーモフィッシャーサイエンティフィック、ロシュ、アジレントテクノロジーズ、マイリアドジェネティクスなどが含まれます。

**Q: ヒト遺伝学市場における遺伝子検査の重要性は何ですか？**
A: 遺伝子検査は大幅に成長すると予測されており、個別化医療や病気診断の進展における重要な役割を示しています。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/human-genetics-market-714*